Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Molecular bilayer structure
Patent
1977-08-11
1979-07-03
Fagelson, Anna P.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Molecular bilayer structure
23230B, 250302, 424 11, 424 12, 424 13, G01N 2138, G01N 3100, G01N 3316
Patent
active
041600169
ABSTRACT:
A novel sensitive method for determining qualitatively and quantitatively the presence of a wide variety of physiologically active organic compounds (ligand) and their receptors is provided. The method employs a reagent whch involves bonding a compound having structural similarity to the compound to be determined (ligand analog) to a fluorescing compound. The unknown compound is referred to as a ligand, the conjugate of the structurally similar compound and fluorescer is referred to as ligand analog-fluorescer, and compounds which recognize a specific structure and bind to such structure are referred to as receptors and are normally antibodies.
The fluorescer which is chosen will have either a change in quantum yield or a change in its emission and/or absorption spectra or all of them, when the ligand analog-fluorescer is bound to receptor, as compared to being unbound. For the purposes of this assay, all that is required is that there be a change in the emission intensity at some wavelength or band of wavelengths.
In performing the assay, the method will vary depending upon whether the analyte is ligand or antiligand. The rate at which antiligand binds to ligand analog-fluorescer or the amount of antiligand bound to ligand analog-fluorescer at equilibrium will be related to the amount of available antiligand in the assay medium. Where the analyte is antiligand, the amount will be directly related to the amount in the sample, and when the analyte is ligand, the amount will be determined by the amount of ligand present in the assay medium in combination with a predetermined amount of antiligand. By observing the amount of reduction in the emission intensity with an unknown amount of analyte in comparison to an assay medium having a known amount of analyte, the amount of analyte in the unknown sample can be determined.
REFERENCES:
patent: 3641235 (1972-02-01), Weiss
patent: 3720760 (1973-03-01), Bennich
patent: 3901654 (1975-08-01), Gross
patent: 3996345 (1976-12-01), Ullman
patent: 3998943 (1976-12-01), Ullman
Williams, Methods in Immunol. & Immunochem., vol. III, 1971, Acad. Press, N.Y., pp. 395-406.
Dandliker, Immunochem., vol. 7, 1970, pp. 799-828.
Brand, Ann. Rev. Biochem., vol. 41, 1972, pp. 843-868.
Stryer, Science, vol. 162, p. 526 (1968).
Smith, FEBS Letters, vol. 77, p. 25 (1977).
Ullman, J. Biol. Chem., vol. 251, p. 4172 (1976).
Fagelson Anna P.
Rowland Bertram I.
Syva Company
LandOfFree
Receptor fluorescent immunoassay does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor fluorescent immunoassay, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor fluorescent immunoassay will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2274708